Blog

MATWIN Unicancer subsidiary announces the awardees of the different panels of experts

Photo taken from MATWIN/LinkedIn

May 27, 2024, 08:26

MATWIN Unicancer subsidiary announces the awardees of the different panels of experts

MATWIN shared a post on LinkedIn:

“Following the 9th edition of MEET2WIN, European Oncology Partnering Convention, MATWIN Unicancer subsidiary celebrates 15 years of innovation against cancer and announces the awardees of the different panels of experts.

A big bravo to all our winners but also all the selected applicants.

MATWIN Board 2024:

Best drug-based innovation: Syndivia Sasha Koniev Sergii Kolodych Jean-Yves Bonnefoy for its innovative GeminiMab technology enhancing the therapeutic index of Antibody-drug-conjugates (ADCs).
Best technology innovation: Novigenix SA Brian Hashemi Pedro Romero Davide Croci Noushin Hadadi for its LITOSeek platform.
Favourite: Arjuna Therapeutics Ross Breckenridge for its Ag5 drug candidate for untreatable cancers.

OUI Investors 2024 :

Best investment potential: Stromacare SAS Georges Rawadi.
Favourite: Serendip innovations Alexandre Hill Vianney Poignavent.

QUICK PITCH 2024:

Fungo Keita Augstkalne for its AR based mobile solution in paediatric oncology.
Persea Sophie de Ferrières Olivier Pellerin for BioTrojan a game-changing treatment for solid cancers.
Actipulse Neuroscience Coralie Dorard Adrien Châtillon for its portable medical device for neuro-oncological disorders.

Thank you all the MATWIN Alumni for their very encouraging testimonials during the event Karine Rossignol Smart Immune Frédéric CAROFF HEPHAISTOS-Pharma Eric Halioua PDC line Pharma Karine CHORRO Phost’in Therapeutics and thank you to our partners for the support offered to the awardees Voisin Consulting Life Sciences (VCLS) leads to development MabDesign Angels Santé.”

Additional information
Source: MATWIN/LinkedIn